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S80With poor survival and high recurrence rates, early-stage lung cancer currently appears to be understaged or un-
dertreated, or both. Although sentinel lymph node biopsy is standard for patients with breast cancer and mela-
noma, its success has been unreliable in non–small cell lung cancer. Sentinel lymph node biopsy might aid in the
identification of lymph nodes at the greatest risk of metastasis and allow for more detailed analysis to select for
patients who might benefit from adjuvant therapy. The early results in our recent clinical trial of patients with
early-stage lung cancer have suggested that near-infrared imaging might offer a platform for reliable sentinel
lymph node identification in these patients. (J Thorac Cardiovasc Surg 2012;144:S80-4)Lung cancer continues to be the leading cause of cancer
death in the United States. Because of the large number of
patients presenting with advanced disease, the 5-year sur-
vival for all patient with lung cancer has improved only
slightly from 11.5% in 1975 to 16.0% in 2003.1 Further-
more, for patients with stage I disease thought to have under-
gone curative resection, the recurrence rates have remained
high, at nearly 40%, with overall 5-year survival of 52.2%.1
When the local lymphnodes are involved, the 5-year survival
decreases by nearly one half, making nodal involvement the
most important prognostic factor. The high incidence of re-
current disease among patient with stage I lung cancer sug-
gests that these patients are currently understaged or
undertreated, or both. To stage the disease more accurately
and identify those patients for whom adjuvant therapymight
be beneficial, detailed lymph node evaluation is prudent.
Sentinel lymph node (SLN) mapping seeks to identify the
first lymph node to harbor metastatic disease from a nearby
tumor and has become an integral part of patient selection
for adjuvant treatment in solid malignancies such as breast
cancer and melanoma. However, no reliable method is avail-
able for SLN evaluation in non–small cell lung cancer
(NSCLC), mostly because of the physical properties of the
lung and thoracic cavity. The ability to identify the lymph no-
des at greatest risk ofmetastatic spread (ie, SLNs) to conduct
more detailed histologic andmolecular analysis would allow
for better patient selection for adjuvant therapy in the hopes
of improving survival and decreasing recurrence. To date, the
use of radioisotopes or blue dye for lymphatic mapping has
not been successfully translated to lung cancer secondarye Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston,
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cedural feasibility. In the present report, we review previous
attempts at SLN identification in non–small-cell lung cancer
and discuss our research using indocyanine green (ICG) dye
and near-infrared (NIR) fluorescence imaging to identify the
SLN in early-stage lung cancer.HISTORY OF SLN MAPPING
Early Greek philosophy supported the hypothesis that
cancer was a local manifestation of a systemic disease.
However, early in the 19th century, Virchow implicated
the lymph nodes in the process of the local spread of solid
tumors to a morewidespread systemic disease. This hypoth-
esis led to the Halstedian model in breast cancer of en bloc
dissection.2 Numerous reports by Gould and colleagues,3
Cabanas,4 and Chiappa and colleagues5 individually identi-
fied lymphatic mapping in parotid, penile, and testicular
cases, respectively; however, the term ‘‘sentinel’’ was fi-
nally coined byWeissbach and Boedefeld6 while examining
the feasibility of limited retroperitoneal lymph node dissec-
tion. The concept of SLN biopsy, as we currently know it,
was first made popular from studies by Morton and col-
leagues7 in 1989. Using blue dye, they performed a feasibil-
ity study in a feline model and translated this into clinical
trials of patients with melanoma. Their results indicated
that biopsy and analysis of SLNs accurately reflected the tu-
mor status of the lymph node basin. Soon after, SLN biopsy
was introduced for breast cancer patients.8 Additional stud-
ies have supported SLN biopsy as a method of identifying
patients at greatest risk of locoregional recurrence and met-
astatic spread and, therefore, most likely to benefit from ad-
juvant therapy.SLN MAPPING IN NON–SMALL CELL LUNG
CANCER
SLN biopsy is currently the standard of care for patients
with melanoma and breast cancer; however, these methods
have not been successfully translated to non–small lung
cancer. Understaging of early lung cancers could be second-
ary to inadequate node sampling because the hilar orery c September 2012
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ICG ¼ indocyanine green
NIR ¼ near-infrared
NSCLC ¼ non–small cell lung cancer
SLN ¼ sentinel lymph nodemediastinal lymph nodes are not completely sampled at tu-
mor resection in nearly 50% of patients.9-11 In addition, the
lymphatic drainage patterns in the lung are highly variable,
making it difficult to predict the draining lymph node basin
that should be sampled. An estimated 20% of SLNs have
bypassed the nearby nodal basin (N1) and skipped to the
mediastinal (N2) stations.12 By removing only the nodes in-
cluded with the resection specimen and failing to sample the
hilar and mediastinal nodes, surgeons are missing these
‘‘skip’’ metastases. However, even if the SLN is removed
at surgery, it is currently processed using conventional his-
tological analysis that often fails to detect micrometastatic
disease. This prospect is particularly worrisome, given
that nearly 16% of patients with histologically node-
negative lung cancer and up to 27.5% of patients with
subcentimeter adenocarcinoma have evidence of microme-
tastatic disease or disseminated tumor cells within the
sampled nodes when analyzed retrospectively with more
time-intensive ‘‘SLN’’ histologic analysis techniques.
Additional immunohistochemistry staining and polymerase
chain reaction evaluation reserved for SLN analysis have
been shown to increase the detection of occult micrometa-
stasis in nodal disease. This is important because untreated
occult micrometastatic disease has been shown to correlate
with a threefold increase in recurrence and a significant de-
crease in patient survival.13 If pathologists knew which no-
des to scrutinize (ie, the SLN), focused histologic and
molecular examination could be performed of these nodes
for evidence of micrometastasis. As such, intraoperative
lymphatic mapping could help guide surgeons directly to
the draining lymph nodes so they can be selected for addi-
tional in-depth analysis.
The conventional methods of SLNmapping have been at-
tempted for NSCLC but have remained unreliable. The first
attempt at SLN biopsy in lung cancer was performed using
blue dye in 1999 by Little and colleagues.14 A total of 36
patients were studied, and only 47% of patients had
a SLN identified. This was attributed to difficulties visual-
izing the dye in anthracotic nodes and poor technique.
The investigators concluded that the rate of SLN identifica-
tion was unacceptably low but equivalent to those from
early melanoma and breast SLN trials. The investigators ad-
vocated for the addition of radiolabeled tracers to improve
the sensitivity and specificity; however, this combination
has also not proved successful.The Journal of Thoracic and CaLiptay and colleagues15 were the first group to report the
use of an intraoperative radioactive tracer in lung cancer
studies in 2000 (Table 1). Their technique of intraoperative
injection of technetium-99m resulted in successful radioiso-
tope migration in 81% of patients and SLN identification in
almost 87%.15 Also, SLN analysis of previously deemed
negative lymph nodes resulted in a diagnosis of occult mi-
crometastatic disease in 24% of these patients. Further-
more, in just more than one third of the patients in whom
a positive SLN was identified, the sentinel node was the
only node with metastatic disease. In addition, 25 of the
104 SLNs had skipped directly to the mediastinum, high-
lighting the difficulty with SLN mapping in the lung. This
initial phase I study with technetium-99m was encouraging
and led to a phase II Cancer and Leukemia Group B multi-
center trial focusing on intraoperative injection of
technetium-99m in patients with suspected stage I NSCLC.
However, the results from that study were discouraging, be-
cause patient accrual was less than 50%, and of those en-
rolled, only 51% of the SLNs were identified. The slow
accrual was attributed to the logistic issues of organizing
nuclear medicine, surgery, and pathology for intraoperative
injection and analysis and the cumbersome regulations for
radioactivity handling. Failure of SLN identification was at-
tributed to the learning curve for the injection technique, the
‘‘shine through’’ effect in which the high radioactive signal
from the tumor injection site produces false-positive results
from increased background signal in nearby tissue, and
background aerosolization of radioactivity.16 After that
study, it was clear that additional measures were needed
to successfully identify the SLN in the thorax.
Various techniques have been attempted to increase the
sensitivity and specificity of SLN identification in lung can-
cer using radioisotopes. From the idea that lymphatic ves-
sels might be disrupted during intraoperative incision and
dissection, preoperative computed tomography-guided in-
jection and intraoperative injection using a transbronchial
approach were proposed. However, Japanese law states
that radioisotopes can only be injected in dedicated rooms.
Thus, preoperative injection of radioisotopes was normally
performed 18 hours before surgery. SLN identification,
however, remained low at only 81% of a total 104 patients
in that study. Failure to reliably identify the SLN was again
attributed to the ‘‘shine through’’ effect of radioactivity
from the tumor into nearby tissues, making detection sepa-
rate from the background difficult, residual radioactivity in
the tracheobronchial tree, and possible decreased lymphatic
density or impaired lymphatic flow in patients with a low
forced expiratory volume in 1 second/forced vital capacity
ratio.17 The technical complications associated with preop-
erative injection included bleeding, pneumothorax, and po-
tential tumor seeding along the injection track. Again,
locating the SLN in lung cancer in every patient remained
an elusive goal.rdiovascular Surgery c Volume 144, Number 3 S81
TABLE 1. Initial sentinel lymph node biopsy mapping studies in
non–small cell lung cancer
Group Year Technique Success rate (%)
Little et al14 1999 Blue dye 47
Liptay et al15 2000 Radioisotope 81
Liptay et al16 2009 Radioisotope 51
Noromi et al17 2007 Preoperative radioisotope 81
Schmidt et al18 2002 Intraoperative blue
dye/radioisotope
81
Tiffet et al19 2005 Intraoperative blue
dye/radioisotope
54
FIGURE 1. Near-infrared imaging. The light source of normal white light
and near-infrared fluorescence is reflected off the surgical field and col-
lected by the camera, producing a real-time merged image.
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ing both blue dye and radioisotopes to aid in the detection of
the SLN in patients with lung cancer. Schmidt and col-
leagues18 used intraoperative injection of both blue dye
and technetium-99m to identify the mediastinal lymph no-
des. However, again, the rate of SLN identification was
only 81%.18 The second group, Tiffet and colleagues,19
studied intraoperative injection of both markers, identifying
SLN in only 13 (54%) of 24 patients, with some patients ex-
hibiting only blue dye or technetium-99mmigration and not
both markers.19 These previous approaches have demon-
strated the technical difficulty of visualizing blue dyewithin
the anthracotic nodes and the differences in anatomy that
make use of Geiger counters to identify radioisotopes diffi-
cult. In addition, the use of radioactivity poses a biologic
risk to the surgeon, operating room personnel, patient, and
pathologist and is limited by the ‘‘shine through’’ to nearby
structures. As a standard approach to the thousands of pa-
tients with lung cancer, this is not an ideal solution. The
poor reliability negates the clinical utility of these ap-
proaches and new innovations are needed.
NIR IMAGING
Recent success with ICG in lymph node mapping in pre-
clinical trials involving animal models and clinical trials of
breast cancer have renewed the interest in SLN biopsy in
NSCLC.20,21 NIR fluorescence uses safe NIR excitation to
provide simultaneous intraoperative imaging of visible
reflected light and the NIR fluorescence emitted from ICG
(Figure 1). ICG can quickly and reliably migrate to draining
lymph node basins, permitting rapid and accurate SLN iden-
tification in a real-time intraoperative setting. Invisible NIR
light penetrates into tissue, detecting fluorescent objects at
a depth of 1 cm in solid tissue. By maintaining separation
of the visible and NIR fluorescent light, it is possible to si-
multaneously acquire color and NIR fluorescence images
and to overlay the 2 images. Thus, a single, intraoperative
procedure is available to visualize SLNs, in which the surgi-
cal field remains unaltered, without additional radiation risk
to the patient or operating staff. To date, NIR-guided SLN
detection in nonthoracic systems has been characterized
by the identification of the SLN using NIR technology andS82 The Journal of Thoracic and Cardiovascular Surgconcurrent real-time videoscopic images of the necessary
anatomic landmarks required for safe and accurate surgical
dissection, low background signal from biologic tissue,
a nearly 100% sensitivity owing to the high signal/noise ra-
tio in the node, and successful identification of a single SLN
station in more than 90% of cases.
TECHNIQUE
In our phase I clinical trial, we assessed the safety and
feasibility of NIR imaging using ICG for SLN identification
in NSCLC in 29 patients. From the results of large animal
studies, our initial technique consisted of peritumoral sub-
pleural injection of low-dose ICG (3.8 mg) coupled with
fresh frozen plasma under direct visualization using the
open-platform fluorescence-assisted resection and explora-
tion camera. After injection, the surgeon proceeded with the
planned operation, avoiding excision of the tumor or manip-
ulation of the lymphatic drainage system while the ICG was
migrating within the lymphatic channels to the SLN for at
least 5 minutes and for up to 20 minutes. Inconsistent visu-
alization of migration and/or SLN identification led to the
following alterations of our initial technique.
Imaging Platform
At the onset of our trial, most lung resections were per-
formed through a thoracotomy, making the open FLAREery c September 2012
FIGURE 2. A, After peritumoral injection of indocyanine green, near-infrared imaging can be used to identify sentinel lymph nodes intraoperatively. After
dissection of the lymph node, ex vivo imaging confirms indocyanine green uptake in the lymph node in (B), merged near-infrared and visual light image, and
(C) pure near-infrared image.
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shifted toward minimally invasive surgery, the imaging
platform has also changed because we now use the
10-mm thoracoscope (Novadaq SpyScope, Richmond, Brit-
ish Columbia, Canada). Using both an open platform
(FLARE, n ¼ 17) and thoracoscopic (Novadaq SpyScope)
NIR system (n¼ 12), we have been able to perform concur-
rent video and NIR imaging intraoperatively.Coupling Agent
Adsorption of ICG to human serum albumin results in an
increased hydrodynamic diameter and has the effect of in-
creasing fluorescence, leading to improved SLN detection.
Recent publications using ICG and NIR imaging for SLN
mapping in breast cancer have used ICG coupled with albu-
min rather than fresh frozen plasma.20 Owing to the poten-
tial risks of blood transfusion reactions and infection with
fresh frozen plasma, we have changed our coupling agent
to albumin without any difference in image quality resulting
from the carrier protein.Injection Depth
The lymphatic pathways of the lung are divided into su-
perficial and deep vessels. The superficial system is the
main system of lymphatic drainage and includes subpleural
vessels and collecting systems that drain the segmental and
lobar regions to the bronchopulmonary nodes. The deep
system is composed of lymph capillaries draining the inter-
lobular, perivascular, and peribronchial connective tissues
to the bronchopulmonary lymph nodes but to a lesser de-
gree.22-24 With this knowledge of the superficial lymphatic
system, our initial technique consisted of shallow,
subpleural injections. This technique often resulted in
spillage of ICG from the injection site, with staining of the
lung parenchyma and failure of lymphatic migration.The Journal of Thoracic and CaSimilar issues were reported by others using NIR imaging
for lung cancer, and a clip was placed at the injection site
in an attempt to stop the leakage from the injection site.25
We have found that one can usually circumvent this issue
by injecting to depths of 1 cm with a fine gauge needle.Lung Ventilation
Finally, we noted consistent visualization of the injection
site but unreliable lymphatic migration when injected into
deflated lung parenchyma. This difference was attributed
to the decreased lymphatic flow in a nonventilated lung.
Therefore, we transiently ventilated the lung. After injection
of ICG, a short period of ventilation (<3 minutes) was per-
formed, leading to improved consistency of lymphatic mi-
gration and SLN identification using NIR imaging
(Figure 2).26,27
These important technical details for successful NIR im-
aging in the lung have not previously been explored or
reported in published studies. Our technique currently con-
sists of intraparenchymal, peritumoral injection, followed
by a short period of ventilation to improve lymphatic flow
of ICG. Using a dose-escalation study, the best results
have been obtained with the injection of 1 mL of 1 mg/mL
ICG/albumin. As wemove to phase II of the study, our goals
are to confirm the reproducibility of these findings in amuch
larger group of patients; to determinewhether the SLN iden-
tified using NIR imaging is currently being removed as
a part of the conventional lymphadenectomy; and to assess
whether focused SLN analysis can identify occult metastatic
disease in patients identified as having ‘‘node-negative’’ dis-
ease using current non-SLN techniques.CONCLUSIONS
Advances in lung cancer are needed to improve patient
outcomes. The identification of the SLN and concomitantrdiovascular Surgery c Volume 144, Number 3 S83
Session VIII: Innovation and the Future Gilmore et alfocused in-depth histologic analysis of this node or nodes in
search of occult micrometastatic disease could result in im-
proved survival because selected patients could receive ad-
juvant therapy for previously undetected occult nodal
disease. The current phase I trial has established the feasi-
bility of SLN mapping in patients with lung cancer and
has demonstrated that NIR mapping can be achieved in
real time using a minimally invasive, intraoperative ap-
proach. Studies are underway to assess the optimal ICG
dosing and the effect of SLN biopsy results on adjuvant
therapy plans and overall outcomes in patients with early
NSCLC staged using this technology.References
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